FierceBiotech8d
Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Business Insider15d
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
in February 2024 due to a serious adverse event (SAE) of liver injury requiring transplant in one patient in the AD trial. No liver toxicity nor other treatment-related SAEs were reported in any other ...